Serum uric acid levels in patients with relapsing-remitting multiple sclerosis

European Journal of General Medicine

Volumn 6, Issue 3, 2009, Pages 166-169

  Altinkaynak, Konca ^a,b   Varoǧlu, Asuman Orhan ^a,b   Aksoy, Hülya ^a,b   Deniz, Orhan ^a,b   Aksoy, Asude ^a,b  

^a ATATÜRK UNIVERSITY   (Turkey)

^b Private Hayat Hospital   (Turkey)

Author keywords

Activity of multiple sclerosis; Endogenous antioxidant; Pathogenesis; Uric acid

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; URIC ACID;

ANTIOXIDANT ACTIVITY; ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; RELAPSE; REMISSION; URIC ACID BLOOD LEVEL;

EID: 73249135365     PISSN: 13043889     EISSN: None     Source Type: Journal    
DOI: 10.29333/ejgm/82663     Document Type: Article

References (28)

1. Lublin FD and Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996; 46: 907-9.
2. Staub M. Uric acid as a scavenger in oxidative stress. Orv Hetil 1999; 140: 275-9.
3. Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci 1998; 95: 675-80.
4. Langeman H, Kabiersch A, Newcombe J. Measurement of low-molecular weight antioxidants, uric acid, tyrosine and triptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol 1992; 32: 248-52.
5. Torreilles F, Salman-Tabcheh S, Guerin M, et al. Neurodegenerative disorders: The role of peroxynitrite, Brain Res Rev 1999; 30: 153-63.
6. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitriteinduced membrane lipid peroxidation: The cytotoxic potential of superoxide end nitric oxide. Arch Biochem. Biophys 1991; 288: 481-7.
7. Spitsin S, Hooper DC, Mikheeva T, et al. Uric acid levels in patients with multiple sclerosis: Analysis in mono-and dizygotic twins, Mult Scler 2001; 7: 165-6.
8. Toncev G, Milicic B, Toncev S, et al. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood- brain barrier dysfunction. Eur J Neurol 2002; 9: 221-6.
9. Sotgiu S, Pugliatti M, Sanna A, et al. Serum uric acid and multiple sclerosis. Neurol Sci 2002; 23: 183-8.
10. Drulovic J, Dujmovic I, Stojsavljevic N, et al. Uric acid levels in sera from patients with multiple sclerosis. J Neurol 2001; 248: 121-6.
11. Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, Dimitrakopoulos A, Karouli M, Vassilopoulos D. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 2006; 108: 527-31.
12. W.I. McDonald A, Compston G, Edan D, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
13. Kurtzke JF, Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
14. Patty DW, Magnetic Resonance in Multiple sclerosis, Curr Opin Neurol Neurosorg 1993; 6: 202-8.
15. Jelic-Ivanovic Z, Spasic S, Majkic-Singh N, et al. Effects of some anti-inflammatory drugs on 12 blood constituents: Protocol for the study of in vivo effects of drugs. Clin Chem 1985; 31: 1141-3.
16. Langford HG, Blaufox MD, Borhani NO, et al. Is thiazide-produced uric acid elevation harmful. Arch Intern Med 1987; 147: 645-9.
17. Newcombe J, Li H, Cuzner ML. Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: Implications for pathogenesis. Neuropathol Appl. Neurobiol 1994; 20: 152-62.
18. Inoue S, Kawanishi S, Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide FEBS Lett 1995; 371: 86-8.
19. Proctor P. Similar functions of uric acid and ascorbate in man?. Nature (London) 1970; 228: 868.
20. Church WH and Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: Effect of dopamine oxidation. Brain Res Bull, 1994; 33: 419-25.
21. Karg E, Klivenyi P, Nemeth I, et al. Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol, 1999; 246: 533-9.
22. Zamani A, Rezaei A, Khaeir F, Hooper DC. Serum and cerebrospinal fluid uric acid levels in multiple sclerosis patients. Clin Neurol Neurosurg. 2008 May 7.
23. Guerrero AL, Martín-Polo J, Laherrán E, et al. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 2008; 15: 394-7.
24. Peng F, Zhang B, Zhong X, et al. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 2008; 14: 188-96.
25. Mattle HP, Lienert C, Greeve I. Uric acid and multiple sclerosis. Ther Umsch. aSep, 2004: 553-5.
26. Kanabrocki EL, Ryan MD, Hermida RC, et al. Uric acid and renal function in multiple sclerosis. Clin Ter 2008; 159: 35-40.
27. Constantinescu CS, Freitag P, Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 2000; 6: 378-81.
28. Karg E, Klivenyi P, Nemeth I, et al. Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 1999; 246: 533-9.